Product

Dexamethasone-Darnitsa

2 forms: eye drops, solution. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form	Dose	Frequency	Georgia
1 mg/ml (0.1%), Eye drops	No label dose in the reference yet	-	Georgia Yes, human In force until 23 Jun 2031 Human (Ministry of Health, RAMA) In the register: დექსამეტაზონი-დარნიცა 1 მგ/მლ (0.1%), თვალის წვეთები 10 მლ № რ-045750 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Dexamethasone-Darnitsa 1 mg/ml (0.1%), Eye drops eye drops 10 ml, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea 6.8/10 Situational / acceptable vetman assessment Dexamethasone-Darnitsa 1 mg/ml (0.1%), eye drops 10 ml, human medicine Assessed clinical scopeDog · Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea · Into the eye Care settingVeterinarian-directed clinic or home treatment after slit-lamp or magnified examination, fluorescein staining and intraocular-pressure assessment where relevant, with scheduled early recheck and taper based on response vetman score 6.8/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-045750 · Verified on 16 Oct 2026 Off-label use A useful potent topical steroid for a diagnosed, noninfectious steroid-responsive eye disease when the cornea is intact. Its value depends on examination rather than brand familiarity: stain before treatment, exclude or control infection, monitor pressure and response, taper longer courses, and stop immediately if pain, discharge or corneal damage emerges. Regulatory and scientific credibility5.5/10 This exact human 0.1% ophthalmic product has a sourced current Georgian registration and identifiable formulation and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Veterinary use is off-label, although an EU-authorised dog/cat veterinary dexamethasone eye-drop solution supports the species, route and concentration. Clinical efficacy8.0/10 Topical 0.1% dexamethasone is a standard, cornea-penetrating veterinary corticosteroid for noninfectious anterior ocular inflammation. Current canine data support improvement in moderate-to-severe follicular conjunctivitis and combination therapy for chronic superficial keratitis, while established use covers anterior uveitis, immune-mediated keratitis and episcleritis; diagnosis and cause-directed therapy determine benefit. Safety and tolerability6.0/10 Correctly selected use is usually locally tolerable, but corticosteroids delay epithelial healing, increase collagenase activity and can convert an occult abrasion into a melting ulcer. Repeated treatment can increase intraocular pressure, promote infection, cataract and steroid keratopathy, and systemic absorption with cortisol suppression is documented after four-times-daily dosing. Clinical practicality8.0/10 A ready-to-use solution and standard dropper provide a directly deliverable ocular dose with no weight calculation. Frequent initial dosing, atraumatic restraint, avoiding tip contact, spacing multiple eye medicines, storage/open-bottle rules and scheduled re-examination still determine whether treatment is practical and safe. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Perform fluorescein staining before starting and whenever new pain develops. Do not use topical dexamethasone with a corneal abrasion, ulcer, descemetocele, melting ulcer, perforation or unhealed penetrating injury; it delays epithelial repair and can accelerate collagenolysis. Do not use as steroid monotherapy for an undiagnosed red eye or untreated bacterial, fungal, mycobacterial, parasitic or viral ocular infection. Establish and treat the cause; immunosuppression can mask progression and allow rapid loss of corneal integrity. Reassess the diagnosis urgently if blepharospasm, discharge, corneal clouding, focal staining, vision change or worsening redness appears; stop dexamethasone until ulceration and infection have been excluded. Measure intraocular pressure when glaucoma is possible and during repeated or prolonged treatment. Topical dexamethasone can raise pressure, cause glaucoma or cataract and promote steroid keratopathy; monitor the cornea, lens and treatment response rather than renewing indefinitely. Ophthalmic dexamethasone is systemically absorbed. Four-times-daily dosing for 14 days suppressed cortisol in healthy dogs; use the lowest effective frequency, consider nasolacrimal occlusion, and review diabetes, hyperadrenocorticism, infection risk and concurrent systemic corticosteroids. Use an indication-appropriate initial frequency and recheck early; severe anterior inflammation may need frequent treatment, whereas chronic immune-mediated disease requires response-guided tapering. Do not stop a prolonged course abruptly or continue unchanged without confirming control. This score covers diagnosed steroid-responsive ocular inflammation as a clinical class, not every human-label indication and not posterior-segment disease that topical drops cannot adequately reach. Lack of response should trigger diagnostic reassessment, not automatic dose escalation. Avoid touching the dropper tip to the eye, lashes or skin; use one bottle per patient where contamination is plausible and separate different eye drops by at least several minutes. Shake suspension products thoroughly before every dose. Safety of these exact human products in pregnant or lactating dogs and cats has not been established. Use only after a documented veterinary benefit-risk assessment, especially for prolonged or bilateral treatment that increases systemic exposure. Assessment sources Dexamethasone eye-drop market audit2026 Maxidex 0.1% SmPC2026 Dexavet veterinary authorisation2026 MSD ophthalmic steroids2026 Canine and feline uveitis review2002 Canine ophthalmic steroid absorption2022 Canine follicular conjunctivitis2023 Canine CSK dexamethasone study2021 ABCD feline herpesvirus guideline2009 Canine steroid keratopathy2024 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea 6.2/10 Situational / acceptable vetman assessment Dexamethasone-Darnitsa 1 mg/ml (0.1%), eye drops 10 ml, human medicine Assessed clinical scopeCat · Ophthalmic dexamethasone for diagnosed noninfectious steroid-responsive conjunctival, corneal or anterior-segment inflammation after complete examination and a fluorescein-negative intact cornea · Into the eye Care settingVeterinarian-directed clinic or home treatment after slit-lamp or magnified examination, fluorescein staining and intraocular-pressure assessment where relevant, with scheduled early recheck and taper based on response vetman score 6.2/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-045750 · Verified on 16 Oct 2026 Off-label use A useful potent topical steroid for a diagnosed, noninfectious steroid-responsive eye disease when the cornea is intact. Its value depends on examination rather than brand familiarity: stain before treatment, exclude or control infection, monitor pressure and response, taper longer courses, and stop immediately if pain, discharge or corneal damage emerges. Regulatory and scientific credibility5.5/10 This exact human 0.1% ophthalmic product has a sourced current Georgian registration and identifiable formulation and manufacturer; exhaustive current checks record no exact EU/EEA, GB or US registration. Veterinary use is off-label, although an EU-authorised dog/cat veterinary dexamethasone eye-drop solution supports the species, route and concentration. Clinical efficacy7.0/10 Topical 0.1% dexamethasone is an established cornea-penetrating corticosteroid for selected noninfectious feline anterior ocular inflammation, including immune-mediated keratitis, conjunctival disease and anterior uveitis. Direct controlled feline efficacy data are limited, and latent FHV-1 or infectious disease can make an apparently inflammatory presentation steroid-inappropriate. Safety and tolerability5.0/10 Corneal ulceration or untreated infection creates a serious local hazard, and feline herpesvirus may reactivate with topical steroid exposure, causing ulceration or sequestrum. Longer treatment can increase intraocular pressure, delay healing, promote infection or cataract and cause systemic glucocorticoid exposure; feline product-specific safety data are limited. Clinical practicality8.0/10 A ready-to-use solution and standard dropper provide a directly deliverable ocular dose with no weight calculation. Frequent initial dosing, atraumatic restraint, avoiding tip contact, spacing multiple eye medicines, storage/open-bottle rules and scheduled re-examination still determine whether treatment is practical and safe. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Perform fluorescein staining before starting and whenever new pain develops. Do not use topical dexamethasone with a corneal abrasion, ulcer, descemetocele, melting ulcer, perforation or unhealed penetrating injury; it delays epithelial repair and can accelerate collagenolysis. Do not use as steroid monotherapy for an undiagnosed red eye or untreated bacterial, fungal, mycobacterial, parasitic or viral ocular infection. Establish and treat the cause; immunosuppression can mask progression and allow rapid loss of corneal integrity. Topical corticosteroids can reactivate latent feline herpesvirus and precipitate ulcerative keratitis or corneal sequestrum. In a cat with compatible history or dendritic/geographic disease, stop steroid treatment and investigate/treat FHV-associated disease before considering further immunosuppression. Measure intraocular pressure when glaucoma is possible and during repeated or prolonged treatment. Topical dexamethasone can raise pressure, cause glaucoma or cataract and promote steroid keratopathy; monitor the cornea, lens and treatment response rather than renewing indefinitely. Ophthalmic dexamethasone is systemically absorbed. Four-times-daily dosing for 14 days suppressed cortisol in healthy dogs; use the lowest effective frequency, consider nasolacrimal occlusion, and review diabetes, hyperadrenocorticism, infection risk and concurrent systemic corticosteroids. Use an indication-appropriate initial frequency and recheck early; severe anterior inflammation may need frequent treatment, whereas chronic immune-mediated disease requires response-guided tapering. Do not stop a prolonged course abruptly or continue unchanged without confirming control. This score covers diagnosed steroid-responsive ocular inflammation as a clinical class, not every human-label indication and not posterior-segment disease that topical drops cannot adequately reach. Lack of response should trigger diagnostic reassessment, not automatic dose escalation. Avoid touching the dropper tip to the eye, lashes or skin; use one bottle per patient where contamination is plausible and separate different eye drops by at least several minutes. Shake suspension products thoroughly before every dose. Safety of these exact human products in pregnant or lactating dogs and cats has not been established. Use only after a documented veterinary benefit-risk assessment, especially for prolonged or bilateral treatment that increases systemic exposure. Assessment sources Dexamethasone eye-drop market audit2026 Maxidex 0.1% SmPC2026 Dexavet veterinary authorisation2026 MSD ophthalmic steroids2026 Canine and feline uveitis review2002 Canine ophthalmic steroid absorption2022 Canine follicular conjunctivitis2023 Canine CSK dexamethasone study2021 ABCD feline herpesvirus guideline2009 Canine steroid keratopathy2024 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Dexamethasone1 mg/ml Formulation Type Eye drops Administration route Into the eye Manufacturer Darnitsa · Ukraine Registration Georgia Yes, human In force until 23 Jun 2031 Human (Ministry of Health, RAMA) In the register: დექსამეტაზონი-დარნიცა 1 მგ/მლ (0.1%), თვალის წვეთები 10 მლ № რ-045750 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026
4 mg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 20 Aug 2031 Human (Ministry of Health, RAMA) In the register: დექსამეტაზონი-დარნიცა 4 მგ/მლ, 1 მლ ამპულა № რ-046182, რ-034187 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Dexamethasone-Darnitsa 4 mg/ml, Solution 1 ml ampoule, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care 6.1/10 Situational / acceptable vetman assessment Dexamethasone-Darnitsa 4 mg/ml, 1 ml ampoule, human medicine Assessed clinical scopeDog · Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care · IV,IM Care settingVeterinary clinic or hospital use after diagnosis and contraindication review, with exact small-volume measurement, route-specific administration, infection management and clinical/metabolic monitoring vetman score 6.1/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-046182, რ-034187 · Verified on 16 Oct 2026 Off-label use A useful, precisely measurable clinic formulation when a diagnosed condition genuinely warrants parenteral dexamethasone and oral treatment is unsuitable. Its value is diagnosis-dependent, veterinary use of the exact human ampoule is off-label, and routine use for uncomplicated allergy or anaphylaxis is not supported; screen contraindications and avoid NSAID overlap. Regulatory and scientific credibility5.5/10 The exact 4 mg/ml human ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, but no current exact EU/EEA, GB or US registration was found. Animal use is off-label and formulation-specific veterinary evidence is absent. Clinical efficacy6.0/10 Dexamethasone is a potent, established veterinary anti-inflammatory glucocorticoid and short systemic courses can be useful for selected severe inflammatory or immune-mediated disease. Benefit varies sharply by diagnosis: current RECOVER guidance recommends against routine glucocorticoids for uncomplicated allergy and anaphylaxis, and evidence does not validate every broad historical use or this exact human ampoule. Safety and tolerability5.5/10 A single selected dose is usually tolerated, but dexamethasone is long acting and highly potent. It can worsen infection, hyperglycaemia, gastrointestinal ulceration, fluid/electrolyte disturbance, delayed healing and HPA suppression; pregnancy, diabetes, hyperadrenocorticism and major cardiac, renal, ocular or ulcer disease materially change the benefit-risk. Clinical practicality8.0/10 The sterile 4 mg/ml, 1 ml ampoule supports rapid IV or IM clinic administration and avoids a prolonged home regimen. At the veterinary 0.1 mg/kg comparator dose it requires only 0.025 ml/kg, so very small patients need a precise low-dead-space syringe; verify the exact insert, excipients, compatibility and single-use handling. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use systemic dexamethasone routinely for uncomplicated allergic reactions or anaphylaxis. Current RECOVER guidance recommends against routine glucocorticoids in both settings; treat anaphylaxis immediately with epinephrine and indicated resuscitation rather than delaying definitive therapy. Avoid concurrent NSAIDs and allow an appropriate washout when switching. The combination materially increases gastrointestinal ulceration, perforation and bleeding risk; review aspirin, meloxicam, carprofen, firocoxib and every other anti-inflammatory exposure. Do not suppress inflammation before excluding or actively treating relevant bacterial, fungal, viral or parasitic infection. Dexamethasone can mask progression, impair host defence and delay wound healing; avoid routine use in systemic infection or viraemia without a compelling, managed indication. Avoid or undertake only an exceptional documented benefit-risk decision in diabetes mellitus, hyperadrenocorticism, gastrointestinal or corneal ulceration, glaucoma, osteoporosis, major cardiac or renal dysfunction and known corticosteroid/excipient hypersensitivity. Do not use routinely during pregnancy: early exposure can cause fetal abnormalities and late exposure can precipitate abortion or premature parturition. Use in growing, lactating, geriatric or debilitated patients only after an individual benefit-risk assessment. Do not combine with a live attenuated vaccine and avoid use around vaccination according to the applicable product information. Immunosuppression can reduce vaccine response; review other immunosuppressants and exposure to infectious disease. Dexamethasone is long acting and suppresses the hypothalamic-pituitary-adrenal axis. Do not use alternate-day dexamethasone as an HPA-sparing strategy; after repeated or prolonged treatment taper rather than stop abruptly, and prefer a shorter-acting corticosteroid when long-term therapy is necessary. Monitor thirst, urination, appetite, vomiting, diarrhoea or melaena, behaviour, body weight, blood pressure, glucose and electrolytes according to dose and duration. Review potassium-depleting diuretics, insulin needs, anticonvulsants and other medicines whose effect can change. This is a 4 mg/ml human 1 ml ampoule, twice the concentration of the 2 mg/ml veterinary comparator. At 0.1 mg/kg, volume is 0.025 ml/kg: use a precise low-dead-space syringe, confirm IV versus IM intent and the exact insert/excipients, do not share a breached single-use ampoule and discard the remainder. Assessment sources Dexamethasone ampoule market audit2026 Dexamethasone 4 mg/mL human label2026 VMD SPC 20252025 VMD SPC 20252025 RECOVER allergy/anaphylaxis2026 AAHA allergic disease guideline2023 MSD corticosteroids2026 VetCompass glucocorticoid safety2020 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care 6.1/10 Situational / acceptable vetman assessment Dexamethasone-Darnitsa 4 mg/ml, 1 ml ampoule, human medicine Assessed clinical scopeCat · Parenteral dexamethasone for a diagnosed acute or severe inflammatory, allergic or immune-mediated condition when systemic glucocorticoid treatment is justified and oral therapy is unsuitable; not routine uncomplicated allergy or anaphylaxis care · IV,IM Care settingVeterinary clinic or hospital use after diagnosis and contraindication review, with exact small-volume measurement, route-specific administration, infection management and clinical/metabolic monitoring vetman score 6.1/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-046182, რ-034187 · Verified on 16 Oct 2026 Off-label use A useful, precisely measurable clinic formulation when a diagnosed condition genuinely warrants parenteral dexamethasone and oral treatment is unsuitable. Its value is diagnosis-dependent, veterinary use of the exact human ampoule is off-label, and routine use for uncomplicated allergy or anaphylaxis is not supported; screen contraindications and avoid NSAID overlap. Regulatory and scientific credibility5.5/10 The exact 4 mg/ml human ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, but no current exact EU/EEA, GB or US registration was found. Animal use is off-label and formulation-specific veterinary evidence is absent. Clinical efficacy6.0/10 Dexamethasone is a potent, established veterinary anti-inflammatory glucocorticoid and short systemic courses can be useful for selected severe inflammatory or immune-mediated disease. Benefit varies sharply by diagnosis: current RECOVER guidance recommends against routine glucocorticoids for uncomplicated allergy and anaphylaxis, and evidence does not validate every broad historical use or this exact human ampoule. Safety and tolerability5.5/10 A single selected dose is usually tolerated, but dexamethasone is long acting and highly potent. It can worsen infection, hyperglycaemia, gastrointestinal ulceration, fluid/electrolyte disturbance, delayed healing and HPA suppression; pregnancy, diabetes, hyperadrenocorticism and major cardiac, renal, ocular or ulcer disease materially change the benefit-risk. Clinical practicality8.0/10 The sterile 4 mg/ml, 1 ml ampoule supports rapid IV or IM clinic administration and avoids a prolonged home regimen. At the veterinary 0.1 mg/kg comparator dose it requires only 0.025 ml/kg, so very small patients need a precise low-dead-space syringe; verify the exact insert, excipients, compatibility and single-use handling. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use systemic dexamethasone routinely for uncomplicated allergic reactions or anaphylaxis. Current RECOVER guidance recommends against routine glucocorticoids in both settings; treat anaphylaxis immediately with epinephrine and indicated resuscitation rather than delaying definitive therapy. Avoid concurrent NSAIDs and allow an appropriate washout when switching. The combination materially increases gastrointestinal ulceration, perforation and bleeding risk; review aspirin, meloxicam, carprofen, firocoxib and every other anti-inflammatory exposure. Do not suppress inflammation before excluding or actively treating relevant bacterial, fungal, viral or parasitic infection. Dexamethasone can mask progression, impair host defence and delay wound healing; avoid routine use in systemic infection or viraemia without a compelling, managed indication. Avoid or undertake only an exceptional documented benefit-risk decision in diabetes mellitus, hyperadrenocorticism, gastrointestinal or corneal ulceration, glaucoma, osteoporosis, major cardiac or renal dysfunction and known corticosteroid/excipient hypersensitivity. Do not use routinely during pregnancy: early exposure can cause fetal abnormalities and late exposure can precipitate abortion or premature parturition. Use in growing, lactating, geriatric or debilitated patients only after an individual benefit-risk assessment. Do not combine with a live attenuated vaccine and avoid use around vaccination according to the applicable product information. Immunosuppression can reduce vaccine response; review other immunosuppressants and exposure to infectious disease. Dexamethasone is long acting and suppresses the hypothalamic-pituitary-adrenal axis. Do not use alternate-day dexamethasone as an HPA-sparing strategy; after repeated or prolonged treatment taper rather than stop abruptly, and prefer a shorter-acting corticosteroid when long-term therapy is necessary. Monitor thirst, urination, appetite, vomiting, diarrhoea or melaena, behaviour, body weight, blood pressure, glucose and electrolytes according to dose and duration. Review potassium-depleting diuretics, insulin needs, anticonvulsants and other medicines whose effect can change. This is a 4 mg/ml human 1 ml ampoule, twice the concentration of the 2 mg/ml veterinary comparator. At 0.1 mg/kg, volume is 0.025 ml/kg: use a precise low-dead-space syringe, confirm IV versus IM intent and the exact insert/excipients, do not share a breached single-use ampoule and discard the remainder. Assessment sources Dexamethasone ampoule market audit2026 Dexamethasone 4 mg/mL human label2026 VMD SPC 20252025 VMD SPC 20252025 RECOVER allergy/anaphylaxis2026 AAHA allergic disease guideline2023 MSD corticosteroids2026 VetCompass glucocorticoid safety2020 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Dexamethasone4 mg/ml Formulation Type Solution Administration route Intravenous, Intramuscular Manufacturer Darnitsa · Ukraine Registration Georgia Yes, human In force until 20 Aug 2031 Human (Ministry of Health, RAMA) In the register: დექსამეტაზონი-დარნიცა 4 მგ/მლ, 1 მლ ამპულა № რ-046182, რ-034187 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Dexamethasone

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
0.05–0.2 mg/kg	Dog	Inflammation	By mouth	once daily in the morning	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2025 Open the source ↗
0.1 mg/kg	Dog, Cat	Allergic Reaction	Intramuscular	as needed	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Dexadreson 2 mg/ml Solution for Injection - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2025 Open the source ↗
0.05–0.2 mg/kg	Cat	Inflammation	By mouth	once daily in the evening	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2025 Open the source ↗

Known Contraindications

Critical
Do not use corticosteroids, topically or systemically, while a corneal ulcer is present. They slow healing of the corneal epithelium and can increase collagenase activity, which may turn the ulcer into a melting ulcer.

Sources: MSD Vet Manual
Critical
Do not use dexamethasone in animals with diabetes mellitus or hyperadrenocorticism unless specifically required and closely monitored.

Sources: VMD SPC · VMD
Critical
Do not use in animals with diabetes mellitus or hyperadrenocorticism.

Sources: VMD SPC · VMD
Critical
Do not use dexamethasone in animals with osteoporosis because corticosteroids increase protein catabolism and can reduce bone mass.

Sources: VMD SPC · VMD
Critical
Do not use dexamethasone in animals with cardiac or renal dysfunction, including congestive heart failure, unless specifically required and closely monitored.

Sources: VMD SPC · VMD
Critical
the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage

Sources: VMD SPC · VMD
Critical
Do not use in animals with cardiac or renal dysfunction.

Sources: VMD SPC · VMD
Critical
Do not use in animals with gastro-intestinal ulceration.

Sources: VMD SPC · VMD
Critical
Do not use dexamethasone in animals with glaucoma.

Sources: VMD SPC · VMD
Critical
Do not use systemic dexamethasone in animals with burns unless specifically indicated and closely monitored.

Sources: VMD SPC · VMD
Critical
Do not use dexamethasone during pregnancy because early exposure can cause fetal abnormalities and late exposure can induce abortion or premature parturition.

Sources: VMD SPC · VMD
Critical
Known hypersensitivity to dexamethasone, another corticosteroid, or any excipient is a contraindication.

Sources: VMD SPC · VMD
Critical
Do not use in animals with viral or mycotic infections.

Sources: VMD SPC · VMD
Warning
Use with particular caution in an immunocompromised patient because corticosteroids delay wound healing and can exacerbate an existing infection.

Sources: VMD SPC · VMD
Warning
Corticoids such as dexamethasone should be used with caution in patients with hypertension.

Sources: VMD SPC · VMD
Warning
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian.

Sources: VMD SPC · VMD
Warning
Do not use concomitantly with attenuated alive vaccine dexamethasone should not be used in combination with vaccines or within two weeks after vaccination

Sources: VMD SPC · VMD
Caution
Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover.

Sources: VMD SPC · VMD
Caution
Use cautiously in geriatric or debilitated animals because corticosteroids increase protein catabolism. Prolonged treatment can cause cushingoid changes, including fat redistribution, muscle weakness and atrophy, and osteoporosis.

Sources: VMD SPC · VMD

Known Drug Interactions

Contraindicated Robenacoxib + Dexamethasone
Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.

Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
Major warning Meloxicam + Dexamethasone
The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.

Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.

Sources: VMD SPC · VMD
Major warning Carprofen + Dexamethasone
Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.

Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Sources: FDA
Major warning Dexamethasone + Insulin glargine
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Major warning Dexamethasone + Insulin human
Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.

Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.

Sources: FDA · AAHA
Minor warning Furosemide + Dexamethasone
The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.

Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.

Sources: VMD SPC · VMD
Minor warning Dexamethasone + Torasemide
The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.

Recommendation: Monitor serum potassium.

Sources: VMD SPC · VMD

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Dexamethasone-Darnitsa

Forms and doses2 of 2 in force in Georgia